Oppenheimer & Co. Inc. Sells 2,006 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Oppenheimer & Co. Inc. cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 17.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,474 shares of the company’s stock after selling 2,006 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in CRISPR Therapeutics were worth $322,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of CRSP. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter valued at $30,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at about $36,000. NBC Securities Inc. lifted its stake in shares of CRISPR Therapeutics by 156,300.0% during the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company’s stock worth $53,000 after buying an additional 1,563 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $71,000. Finally, Elkhorn Partners Limited Partnership boosted its holdings in shares of CRISPR Therapeutics by 22.6% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company’s stock worth $150,000 after buying an additional 700 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Up 6.5%

CRISPR Therapeutics stock opened at $51.67 on Thursday. The firm has a fifty day simple moving average of $40.14 and a two-hundred day simple moving average of $40.63. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $63.68. The company has a market capitalization of $4.46 billion, a PE ratio of -11.43 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The business’s quarterly revenue was up 71.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.43) EPS. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several research reports. JMP Securities reissued a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Chardan Capital restated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, June 26th. The Goldman Sachs Group lowered their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $71.75.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider owned 6,068 shares in the company, valued at approximately $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.